MedTrace Logo

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

NCT05949632 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-08-03

No results posted yet for this study

Summary

This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.

Conditions

Interventions

DRUG

INCB099280

Administered as specified in the treatment arm description

DRUG

axitinib

Administered as specified in the treatment arm description

Sponsors & Collaborators

Principal Investigators

  • Philomena Colucci · Incyte Corporation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-16
Primary Completion
2025-06-06
Completion
2025-06-06
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05949632 on ClinicalTrials.gov